Clinical trial
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
NCT00445068 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00445068 |
|---|---|
| Title | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma |
| Official title | A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | LBH589 |
| Enrollment | 38 |
| Start date | Apr 16, 2007 |
| Primary completion | May 19, 2008 |
| Completion | Dec 25, 2009 |
| First posted | Mar 8, 2007 |
| Last update posted | Jul 14, 2021 |
| Countries | Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: